Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Hormonal shifts postpartum, during PMS, or in perimenopause make weight gain more likely
Many extended health plans have added obesity medications to their formularies following the wave of GLP-1 approvals
Dosing and storage instructions were included
Side Effects & Safety Nausea most common (~33% at high doses), dose-dependent, typically improves over time GI effects vomiting, diarrhea, constipation, slowed gastric emptying (GLP-1 class effects) Heart rate changes transient increases observed in trials, peaked at 24 weeks then declined Injection site reactions mild redness or irritation Gallbladder risk rapid weight loss increases gallstone risk (common with any rapid weight loss method) No major safety signals in 48-week trial up to 12 mg weekly At community doses (1.5 mg/week), side effects are notably milder than high-dose trial groups Dosage Chart This dosage chart consolidates the doses reported in published Phase 2 trials and self-reported community protocols, expressed in milligrams (mg) and converted to units on a standard 100-unit / 1mL insulin syringe
US$ 29.50
US$ 27.73
US$ 27.52
US$ 21.69
US$ 29.62
US$ 28.72
US$ 26.65
